What is the current price of PHARM.AS stock?

PHARM.AS stock closed at **€1.60** on 16 Jan 2026, with a day range of **€1.56–€1.60** and volume **13,869,887** shares traded on EURONEXT. Check live feeds for intraday moves.

What does Meyka AI forecast for PHARM.AS stock?

Meyka AI's forecast model projects a 12-month price of **€1.93**, implying **20.48%** upside from **€1.60**. Forecasts are model-based projections and are not guarantees.

What are the main risks for PHARM.AS stock?

Key risks include clinical trial setbacks, regulatory delays, pricing pressure for Ruconest, and stretched valuation given near-zero earnings. A negative earnings surprise could press the price below key support levels.

How does PHARM.AS stock compare to its sector?

PHARM.AS trades at higher P/S and P/B ratios than many small biotech peers but lacks stable earnings. The Healthcare sector average P/E is around **35.38**, while Pharming’s earnings profile keeps its effective PE metrics distorted.

EU Stocks

PHARM.AS Pharming Group (EURONEXT) 16 Jan 2026: Active at €1.60, outlook ahead

ByDanny Kontos January 17, 2026January 17, 2026

PHARM.AS stock closed the EURONEXT session on 16 Jan 2026 at €1.60, up 2.50% on volume of 13,869,887 shares. The move kept the share price above its 50-day average €1.45 and well above the 200-day average €1.12. Market participants named Pharming Group N.V. among the most active European biotech names today, driven by steady Ruconest sales and continued R&D progress. We use trading, valuation and Meyka AI model outputs to frame near-term targets and risk scenarios for investors.